Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Viatris completes $3B divestiture of biosimilars business

Viatris Inc.'s divestiture of its biosimilars business to Biocon was completed Tuesday with a $2 billion cash payment to the Canonsburg pharmaceutical company, the first of an expected $9 billion in divestitures. The terms of the agreement with Biocon Biologics Ltd. also include $1 billion in convertible preferred equity in Biocon Biologics that the companies said amounted to a 12.9% stake in the company plus $335 million in cash in 2024. Viatris (Nasdaq: VTRS) will also provide commercialization and regulatory-related services to Biocon for two years.

Viatris Completes Biosimilars Transaction with Biocon Biologics

Viatris Inc. (NASDAQ: VTRS) today announced that it has closed its transaction with Biocon Biologics Limited ("Biocon Biologics"), creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Viatris and Biocon Biologics have entered a Transition Services Agreement (TSA) pursuant to which Viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for patients, customers

Better Dividend Stock: AbbVie or Viatris?

AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) have a lot more in common than first glances would suggest. The two were both spun off from larger companies and now deliver above-average dividend yields. In AbbVie's case, it is the patent cliff next year for its immunology drug Humira, the top-selling drug last year other than COVID-19 vaccines.

Mittleman Global Value Equity Fund Q3 2022 Report

The Mittleman Global Value Equity Fund (MGVEF) declined 6.5% in Q3 2022, vs. a decline of 0.3% in the MSCI ACW Net Total Return Index. Click here to read the full fund letter.

3 Unstoppable Growth Stocks to Buy and Hold

Three simple words can make you a lot of money over the long run: buy and hold. Here's why they chose Pfizer (NYSE: PFE), Thermo Fisher Scientific (NYSE: TMO), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (Pfizer): Pfizer has grown its top line at an incredible pace over the past two years.

Viatris And Oyster Point: Mylan All Over Again?

VTRS agreed to acquire OYST and Famy Life Sciences for combined $700 million to $750 million. OYST shareholders receive $11 plus a CVR (potentially worth $1-$2) per share.

Viatris Insider Trading Scheme Busted

The executive went through elaborate measures to hide his activity

3 Stocks With Dividends of 3% or More to Buy on the Dip

Fresenius Medical Care (NYSE: FMS), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) have seen their shares slide so far this year. Fresenius, a German company that specializes in healthcare services for kidney dialysis patients, has seen its shares fall more than 54% this year. Fresenius reported third-quarter numbers on Nov. 1, and the results were mixed.

Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q3 2022 Update

Davis Selected Advisers 13F portfolio value decreased from $15.59B to $14.06B this quarter. Read more here.

Viatris Insider Trading Scheme -

GuruFocus Article or News written by Praveen Chawla and the topic is about: The executive went through elaborate measures to hide his activity